EGFR-antibody-supplemented TPF chemotherapy: Preclinical investigations to a novel approach for head and neck cancer induction treatment

Advances in Oto-Rhino-Laryngology

Volumn 62, Issue , 2005, Pages 81-91

  Knecht, Rainald ^a,b   Peters, Silke ^a   Hambek, Markus ^a   Solbach, Christine ^a   Baghi, Mehran ^a   Gstöttner, Wolfgang ^a  

^a GOETHE UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; MONOCLONAL ANTIBODY; TAXOID;

ANIMAL; ARTICLE; CANCER TRANSPLANTATION; COMPARATIVE STUDY; DISEASE MODEL; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG ANTAGONISM; FEMALE; HEAD AND NECK TUMOR; MALE; MORTALITY; MOUSE; MULTIMODALITY CANCER THERAPY; NUDE MOUSE; PATHOLOGY; PROBABILITY; RANDOMIZATION; REFERENCE VALUE; SENSITIVITY AND SPECIFICITY; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; WESTERN BLOTTING;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CISPLATIN; COMBINED MODALITY THERAPY; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HEAD AND NECK NEOPLASMS; MALE; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; PROBABILITY; RANDOM ALLOCATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; REFERENCE VALUES; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; TAXOIDS;

EID: 16644391783     PISSN: 00653071     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Article

References (20)

1. 0 head and neck cancer. J Clin Oncol 1995;13:1493-1500.
2. Haddad R, Tishler RB, Norris CM, Mahadevan A, Busse P, Wirth L, Goguen LA, Sullivan CA, Costello R, Case MA, Posner MR: Docetaxel, cisplatin, 5-fluorouracil (TPF)-based induction chemotherapy for head and neck cancer and the case for sequential, combined-modality treatment. Oncologist 2003;8:35-44.
3. Knecht R, Baghi M, Hambek M, Tesch H, Gstoettner W: Response rate and outcome of a novel induction chemotherapy regimen (TPF) in the first-line therapy of advanced head and neck carcinomas (SCCHN). Proc ASCO 2003;22:50.
4. Fan Z, Baselga J, Masui H, Mendelsohn J: Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well-established A431 cell xenografts. Cancer Res 1993;53:4637-4642.
5. Bier H, Hoffmann T, Hauser U, Wink M, Ochler M, Kovar A, Muser M, Knecht R: Clinical trial with escalating doses of the antiepidermal growth factor receptor humanized monoclonal antibody EMD 72000 in patients with advanced squamous cell carcinoma of the larynx and hypopharynx. Cancer Chemother Pharmacol 2001;47:519-524.
6. Ford AC, Grandis JR: Targeting epidermal growth factor receptor in head and neck cancer. Head Neck 2003;25:67-73.
7. Hambek M, Solbach C, Schnuerch HG, Roller M, Stegmueller M, Sterner-Kock A, Kiefer J, Knecht R: Tumor necrosis factor alpha sensitizes low epidermal growth factor receptor (EGFR)-expressing carcinomas for anti-EGFR therapy. Cancer Res 2001;61:1045-1049.
8. Veterans Affairs Laryngeal Cancer Study Group: Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med 1991;324:1685-1690.
9. Kraus DH, Pfister DG, Harrison LB, Shah JP, Spiro RH, Armstrong JG, Fass DE, Zelefsky M, Schantz SP, Weiss MH, et al: Larynx preservation with combined chemotherapy and radiation therapy in advanced hypopharynx cancer. Otolaryngol Head Neck Surg 1994;111:31-37.
10. Lefebvre JL, Chevalier D, Luboinski B, et al: Larynx preservation in pyriform sinus cancer: Preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. J Natl Cancer Inst 1996;88:890-898.
11. Posner MR, Lefebvre JL: Docetaxel induction therapy in locally advanced squamous cell carcinoma of the head and neck. Br J Cancer 2003;88:11-17.
12. Schmiegel W, Schmielau J, Henne-Bruns D, Juhl H, Roeder C, Buggisch P, Onur A, Kremer B, Kalthoff H, Jensen EV: Cytokine-mediated enhancement of epidermal growth factor receptor expression provides an immunological approach to the therapy of pancreatic cancer. Proc Natl Acad Sci USA 1997;94:12622-12626.
13. Yang X-D, Jia X-C, Corvalan JRF, Wang P, Davis CG, Jakabovits A: Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Res 1999;59:1236-1243.
14. Baselga J, Norton L, Albanell J, Kim Y-M, Mendelsohn J: Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 1998;58:2825-2831.
15. Modjtahedi H, Affleck K, Stubberfield C, Dean C: EGFR blockade by tyrosine kinase inhibitor or monoclonal antibody inhibits growth, directs terminal differentiation and induces apoptosis in the human squamous cell carcinoma HN5. Int J Oncol 1998;13:335-342.
16. Modjtahedi H, Eccles SA, Box G, Styles J, Dean CJ: Antitumor activity of combinations of antibodies directed against different epitopes on the extracellular domain of the human EGFR receptor. Cell Biophys 1993;22:129-146.
17. Mujoo K, Donato NJ, Lapushin R, Rosenblum MG, Murray JL: Tumor necrosis factor α and γ-interferon enhancement of anti-epidermal growth factor receptor monoclonal antibody binding to human melanoma cells. J Immunother 1993;13:166-174.
18. Baselga J, Trigo JM, Bourhis J, Tortochaux J, Cortes-Funes H, Hitt R, Gascon P, Muesser M, Harstrick A, Eckardt A: Cetuximab (C225) plus cisplatin/carboplatin is active in patients with recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN) progressing on a same dose and schedule platinum-based regimen. Proc ASCO 2002;21:900.
19. Sirotnak FM, Zakowski MF, Miller VA, Scher HI, Kris MG: Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 2000;6:4885-4892.
20. Mendelsohn J: The epidermal growth factor receptor as a target for cancer therapy. Endocr Relat Cancer 2001;8:3-9.